Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258932 | 0.73 | ALDH1A1 (0.50) | JAK2CDK2HTR2AHRH1DRD2 | |
| SCHEMBL1678905 | 0.70 | SMN1; SMN2 (0.56) | CDK2ALDH1A1KDM4E | |
| SCHEMBL21258985 | 0.68 | ALDH1A1 (0.44) | JAK2CDK2ALDH1A1KDM4E | |
| SCHEMBL1678955 | 0.67 | CSF1R (0.62) | NUDT1CDK2CSF1RHTR2AHRH1 | |
| SCHEMBL3268357 | 0.67 | NUDT1 (0.43) | NUDT1CDK2CSF1RHTR2AHRH1 | |
| SCHEMBL1679576 | 0.67 | CSF1R (0.62) | NUDT1CDK2CSF1RHTR2AHRH1 | |
| SCHEMBL1991252 | 0.67 | CSF1R (0.62) | NUDT1CDK2CSF1RHTR2AHRH1 | |
| SCHEMBL31080147 | 0.67 | NUDT1 (0.43) | NUDT1CDK2CSF1RHTR2AHRH1 | |
| SCHEMBL18171880 | 0.66 | NUDT1 (0.42) | NUDT1ARJAK2JAK3PGR | |
| SCHEMBL21258928 | 0.66 | CDK2 (0.44) | CDK2CSF1RHTR2AHRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689739-B1 | AZOLE-BASED KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-03-30 | — | — | EP | disclosed |
| EP-1689739-B1 | AZOLE-BASED KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-03-30 | — | — | EP | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-7737143-B2 | Substituted pyrazines as kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-06-15 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099935-A1 | such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases | PRKACA, MAP3K6, PRKDC | NUDT1 596/4885AR 2255/4885JAK2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.